Levels of mRNA transcripts indicating active infection strengthen case for pathogenic role.
Sera drawn before vs. after onset of MS find seropositivity for HHV-6A more likely in MS.
Investigators were surprised that the use of the less toxic CMV specific antiviral did not result in a significant increase in HHV-6-related disease.
Study pools data from nearly 30,000 people with MS.
Guidelines recommend routinely assessing HHV-6 viral load, but not antiviral treatment when HHV-6 reactivation identified.
In contrast, human papillomavirus found more often in urine of bladder cancer patients than in urine of patients with non-cancerous urinary tract conditions.
Combination of viral load and presence of specific polymorphism in the TNF-α gene associated with major depression.
In a surprise, multi-virus cytotoxic T cell therapy trials were terminated early for failure to meet endpoints.
Investigators urge careful monitoring for HHV-6 and ciHHV-6.
Could some complications of CAR-T cell therapy be secondary to HHV-6 infection?
Clearly documented cases of HHV-6 encephalitis have been reported, but some are missed because they were classified as ICAN or because HHV-6 testing was not performed in patients with mental status changes.
While unlikely to trigger the cytokine storm, HHV-6 infection may perpetuate it, and contribute directly to cytopenias and pneumonia.
T-cell responses correlate directly with clinical symptoms, and were better predictors of HHV-6 disease than viral load or total CD3+ counts.
The severity of DIHS/DRESS cases was significantly correlated with the frequency of CD134+ cells.
HHV-6 reactivation much more frequent than reactivation of other herpesviruses.